Analytical Data
-
Gene name
CXCL14/BRAK
- Application
-
Alternative Names
BRAK; SCYB14; BRAK; NJAC; Bolekine; Kec; MIP2-G; MIP2g; BMAC; KS1; Breast And Kidney Expressed Chemokine; Small Inducible Cytokine Subfamily B(Cys-X-Cys)Member 14
-
Species
Rat
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
-
-
Expression Region
Ser23~Glu99
-
Protein Length
Partial
-
Molecular Weight
40kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CXCL14, also known as BRAK (B-Chemokine Regulated by Activation), is a member of the CXC chemokine family with a unique role in modulating immune responses and possessing anti-tumor properties. Initially identified as a gene that is differentially expressed in various cancers, CXCL14 has garnered significant attention due to its potential implications in tumor biology and immune regulation. It is known to attract immune cells such as dendritic cells and T cells, thereby influencing local immune responses and possibly enhancing anti-tumor immunity. Moreover, studies suggest that CXCL14 may play a role in inhibiting tumor growth and metastasis, making it a candidate for cancer immunotherapy. Research has focused on the recombinant production of CXCL14 to study its biological functions in more detail, including its interaction with receptors, signaling pathways, and effects on different cell types. This understanding is crucial for exploring therapeutic applications, especially in cancer treatment, where CXCL14's ability to modulate the tumor microenvironment can be harnessed.
